The International Centers for Precision Oncology Foundation (ICPO) and Munich Precision Oncology GmbH (MPO) have partnered to create a pilot center for radiomolecular cancer treatments in Garching, near Munich. This facility, a collaboration of clinical, academic, and industrial partners, will utilize advanced technology and establish new treatment standards. ICPO will provide training, patient workflow guidelines, and clinical protocols to ensure optimal patient outcomes, using its international center accreditation model. The Munich center will serve as a model for future global centers.
MPO, a newly formed German company with extensive experience in radiomolecular theranostics, will combine medical, scientific, and technical expertise at the Munich Precision Oncology Center. This will include advanced imaging technology, such as a total body PET/CT scanner, and AI-based data analytics.
The center will also facilitate first-in-human studies and clinical trials for novel radiopharmaceuticals, accelerating research and improving patient access to groundbreaking treatments. This will help bring innovative radiotheranostic treatments to patients more effectively.
ICPO CEO Odile Jaume stated the partnership demonstrates the Foundation’s expertise and commitment to expanding access to precision oncology. The Munich pilot center will highlight collaborative efforts, elevate radiomolecular precision oncology’s importance, and improve patient care.
MPO Managing Director Dr. Bent Witte-Reichardt echoed this enthusiasm, emphasizing the center’s role as a model for patient-centered cancer treatment integrating cutting-edge innovation. The goal is to create a replicable model for global cancer care advancement.
About Munich Precision Oncology GmbH (MPO)
Munich Precision Oncology is a German company founded by entrepreneurs with extensive experience in establishing and developing successful companies in the field of radiomolecular theranostics. MPO aims to develop and establish dedicated theranostics centers globally using cutting-edge technology to provide the highest standard in patient care. The pilot center, located near Munich, will be developed in close cooperation with leading clinical, academic, and industrial partners and will serve as a functional demonstrator for the ICPO Foundation.
Media contact MPO GmbH
Paolina Buck
Program Manager Theranostics
E-Mail: info@mp-onco.com
Website:
About ICPO Foundation
The International Centers for Precision Oncology Foundation (ICPO) is a non-profit organization established in 2019 under German law by leading international medical practitioners and life sciences entrepreneurs. Recognizing the shift in cancer care towards personalized approaches, the ICPO Foundation is working to expand global access to Radiomolecular Precision Oncology. The ICPO Foundation aims to create an international network of diagnostic and therapeutic centers using a Social Franchise model. This model incorporates shared expertise, certified education through the ICPO Academy for Theranostics, and standardized processes to ensure best clinical practices worldwide. The ICPO Foundation seeks to empower its centers through a supportive community, making precision oncology accessible to all patients regardless of location or social status.
Learn more about the ICPO Foundation at and the ICPO Academy for Theranostics at
Media contact ICPO Foundation
Susanne Simon
Head of Communication & Community
Email: susanne.simon@icpo.foundation
Phone: + 49 172 8666093
Attachment
